KEY-507-D

KEY-507-D (later designated as JZP-507) is an investigational lower-sodium oxybate oral solution formulation developed by Jazz Pharmaceuticals for the treatment of narcolepsy, specifically targeting cataplexy and excessive daytime sleepiness. It was designed as a 50 percent reduced-sodium alternative to Xyrem (sodium oxybate) to mitigate the cardiovascular risks associated with high chronic sodium intake. In Phase 1 pharmacokinetic studies, KEY-507-D demonstrated bioequivalence to Xyrem. However, Jazz Pharmaceuticals ultimately decided to prioritize the development of JZP-258 (lower-sodium oxybate, marketed as Xywav), which offers a more substantial 92 percent reduction in sodium content, leading to the termination of the JZP-507 program.

Other names

lower-sodium oxybate oral solution